Drug intelligence / Profile preview

paclitaxel + cisplatin + carboplatin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of paclitaxel, cisplatin, and carboplatin. Paclitaxel is a taxane that stabilizes microtubules, preventing cancer cell division. Cisplatin and carboplatin are platinum compounds that form DNA crosslinks, interfering with DNA replication and causing cell death. This combination has been studied in clinical trials for various cancer types, including advanced ovarian cancer and endometrial cancer.

Other names: HIPEC with paclitaxel and cisplatinNACT with paclitaxel and carboplatinneoadjuvant chemotherapy-Shu-Zhong Cui-epithelial ovarian cancer-fallopian tube cancer-primary peritoneal carcinoma

Targets

Microtubule

Beyond the preview

Go deeper on paclitaxel + cisplatin + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + cisplatin + carboplatin.

Explore the full profile